<DOC>
	<DOCNO>NCT02869087</DOCNO>
	<brief_summary>The aim study prospectively collect information evaluate safety performance Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system treatment symptomatic primary atherosclerotic stenosis occlusion superficial femoral artery ( SFA ) .</brief_summary>
	<brief_title>The DESappear Study : Drug Eluting Scaffold</brief_title>
	<detailed_description>This mutli center , prospective , single arm study enrol 60 patient 12 center New Zealand Europe . The purpose prospectively collect information evaluate safety performance Akesys Prava Sirolimus elute bioresorbable scaffold system peripheral arterial disease ( PAD ) Patients treat investigational device follow clinically 1 month , 6 Months , 12 month , 24 month 36 month post procedure . Patients undergo non-invasive assessment Duplex Ultrasound ( DUS ) , Ankle/Brachial Index ( ABI ) measurements complete Walking Impairment Questionnaire ( WIQ ) Quality Life Questionnaire ( VASCUQoL ) follow interval . Data collect via electronic data capture ( EDC ) reportable Events review medical monitor classify use MedDRA system . The information enter research centre source data verify ( monitor ) independent Contract Research Organisation ( CRO . ) A Data Monitoring Committee ( DMC ) appropriately qualified member independent study meet review adjudicate event predetermine interval , accord charter . Primary safety efficacy endpoint evaluate 6 month There formal hypothesis test study , endpoint evaluate 95 % confidence interval around observed point estimate . The endpoint evaluate Kaplan-Meier methodology .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Clinical inclusion criterion : 1 . Subject ≥18 year age . 2 . Subject informed nature study , agree provision , able provide inform consent , agree undergo protocolrequired follow examination requirement . 3 . Subject 's life expectancy least 1 year . 4 . Subject diagnose symptomatic claudication ( RutherfordBecker Clinical Category 24 ) . 5 . For female childbearing potential , negative pregnancy test within 14 day index procedure require 6 . Subject able take P2Y12 receptor antagonist ( e.g . clopidogrel , ticagrelor , prasugrel ticagrelor ) acetylsalicylic acid ( aspirin ) . Angiographic inclusion criterion : 1 . A single , de novo native disease segment SFA 2 . Proximal margin target lesion ≥1 cm distal common femoral artery bifurcation ; distal margin target lesion within SFA . 3 . Vessel diameter ≥5.0 mm ≤6.0 mm evaluate online quantitative vascular angiography ( QVA ) predilatation per core laboratory guideline . 4 . Target lesion diameter reduction ≥50 % 5 . Target lesion length ≤53 mm 6 . Patent inflow artery free significant lesion ( ≥50 % diameter reduction ; 7 . Patent distal popliteal artery free significant lesion ( ≥50 % ) angiographic demonstration least one fully patent distal outflow artery ( anterior tibial , posterior tibial , peroneal ) terminus . Clinical exclusion criterion : 1 . Previous bypass surgery stenting TL ; 2 . Percutaneous open surgical revascularization contralateral iliac infrainguinal artery ≤30 day prior plan index procedure . Iliac artery lesion may treat index procedure necessary approach TL ; 3 . Failure successfully cross target lesion guide wire ; 4 . Subject know abdominal aortic aneurysm &gt; 4 cm diameter , know iliac artery aneurysm &gt; 3 cm diameter , history open surgical abdominal aortic iliac revascularization . 5 . Lesion within adjacent aneurysm presence popliteal aneurysm ; 6 . Subject receive immunosuppression therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus ) ; 7 . Acute limb ischemia ; 8 . History bleed diathesis ; 9 . History hypercoagulability syndrome ; 10 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 ; WBC &lt; 3,000 cells/mm3 ; hemoglobin &lt; 10.0 g/dL ; 11 . Acute chronic renal dysfunction ( creatinine &gt; 2.5 mg/dl &gt; 176 μmol/L ) , chronic hemodialysis ; 12 . Severe liver impairment define total bilirubin ≥3 mg/dl two time increase normal level SGOT/AST SGPT/ALT ; 13 . Known allergy follow : aspirin , clopidogrel , prasugrel , ticagrelor , heparin , contrast agent ( adequately premedicated ) , drug similar sirolimus ( i.e . tacrolimus , everolimus , zotarolimus ) macrolides ; 14 . Subject require planned procedure within 30 day would necessitate discontinuation clopidogrel , prasugrel , ticagrelor ; 15 . Subject chronic Coumadin therapy 16 . Subject plan treatment DES drug coat balloon ( DCB ) within 90 day pre postindex procedure ; 17 . Subject nonambulatory ; 18 . Subject undergone percutaneous intervention coronary , carotid , arterial bed exclusive &lt; 30 day prior plan index procedure . 19 . Subject receive , wait list , organ transplant ; 20 . Subject myocardial infarction ( MI ) within previous 30 day prior plan index procedure ; 21 . Subject stroke within previous 30 day plan index procedure and/or deficit prior stroke limit subject 's ability walk ; 22 . Subject unstable angina define rest angina ECG change ; 23 . Subject groin infection , acute systemic infection treat successfully currently treatment ; 24 . Subject acute thrombophlebitis ( superficial deep ) either extremity ; 25 . Subject medical condition ( e.g. , cancer , congestive heart failure substance abuse ) may cause subject noncompliant protocol requirement confound data interpretation ; 26 . Subject currently participate want participate clinical trial follow 6 month index procedure investigational drug , biologic , device study complete primary endpoint clinically interfere current study endpoint . ( Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial ) ; 27 . Subject unable understand unwilling cooperate study procedure ; 28 . Subject prior minor major amputation either low extremity ; 29 . Subject part vulnerable population , judgment investigator , unable give inform consent reason incapacity , immaturity , adverse personal circumstance lack autonomy ; 30 . Preoperative plan additional treatment target lesion time study procedure alternative therapy drugeluting stent ( DES ) scaffold , laser , atherectomy , cryoplasty , cut balloon , drugeluting balloon , brachytherapy ( vessel preparation uncoated balloon angioplasty allow ) ; 31Plan cardiovascular surgical interventional procedure ≤30 day study procedure include plan treatment contralateral low extremity . Angiographic exclusion criterion : 1 . Target extremity angiographically significant ( &gt; 50 % diameter reduction ) lesion locate target vessel distal target lesion ; 2 . Thrombus target vessel ; 3 . Stenosis ( &gt; 50 % ) occlusion ipsilateral inflow artery ; 4 . Angiographic evidence thromboembolism atheroembolism treatment ipsilateral iliac lesion , cross predilating target lesion ; 5 . Target lesion calcification either follow characteristic : Circumferential orientation , Thickness &gt; 2 mm ( radially ) within wall target lesion . 6 . Failure achieve less 30 % residual stenosis balloon predilation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>